US 12,391,770 B2
Compositions and methods comprising antibodies that bind to covalent peptide conjugates
Shohei Koide, New York, NY (US); Benjamin Neel, New York, NY (US); Carmine Fedele, New York, NY (US); Kai Wen Teng, Flushing, NY (US); Akiko Koide, New York, NY (US); Takamitsu Hattori, West New York, NJ (US); and Lorenzo Maso, New York, NY (US)
Assigned to NEW YORK UNIVERSITY, New York, NY (US)
Filed by New York University, New York, NY (US)
Filed on Feb. 23, 2024, as Appl. No. 18/585,676.
Application 18/585,676 is a continuation of application No. 18/547,623, previously published as PCT/US2022/018171, filed on Feb. 28, 2022.
Claims priority of provisional application 63/253,499, filed on Oct. 7, 2021.
Claims priority of provisional application 63/154,627, filed on Feb. 26, 2021.
Prior Publication US 2024/0327542 A1, Oct. 3, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/44 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01)
CPC C07K 16/44 (2013.01) [A61K 47/6849 (2017.08); C07K 16/2833 (2013.01); C07K 2317/56 (2013.01); C07K 2317/626 (2013.01)] 8 Claims
 
1. A method comprising: administering to a human subject a pharmaceutical composition comprising an antibody or antigen binding fragment thereof, wherein the human subject has been pretreated with AMG510 and has a cancer that expresses a G12C mutant KRAS protein that comprises the amino acid sequence of SEQ ID NO: 1, wherein the antibody or antigen binding fragment thereof binds to a peptide conjugate in complex with a major histocompatibility complex (MHC) that is HLA-A*03:01, wherein the peptide conjugate comprises a peptide from the G12C mutant KRAS protein that comprises the amino acid sequence of SEQ ID NO: 1 covalently linked to the AMG510, and wherein the antibody or antigen binding fragment thereof comprises
(i) a heavy chain variable region (VH) comprising
a heavy chain complementarity determining region 1 (HC CDR1) having the amino acid sequence set forth in SEQ ID NO: 169,
a HC CDR2 having the amino acid sequence set forth in SEQ ID NO: 170, and
a HC CDR3 having an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NOs: 375-420; and
(ii) a light chain variable region (VL) comprising
a light chain (LC) CDR1 having the amino acid sequence set forth in SEQ ID NO: 166,
a LC CDR2 having the amino acid sequence set forth in SEQ ID NO: 167, and
a LC CDR3 having an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NOs: 332-374.